Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 62

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 62
---
’ and officers’ insurance policy pursuant to which our directors and officers are insured against liability for actions taken in their capacities as directors and officers. We believe that these provisions in our articles of continuance and Bylaws and these indemnity agreements are necessary to attract and retain qualified persons as directors and officers. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or control persons, in the opinion of the SEC, such indemnification is against public policy, as expressed in the Securities Act and is therefore unenforceable. 43

PAY VERSUS PERFORMANCE As required by Item 402(v) of Regulation S-K,we are providing the following information about the relationship between executive compensation actually paid and our financial performance. For the most recently completed fiscal year, we did not use any “financial performance measures” as defined Item 402(v) of Regulation S K to link compensation paid to our named executive officers. Accordingly, we have omitted the tabular list of financial performance measures and the table below does not include a column for a “Company-Selected Measure” as defined in Item 402(v) of Regulation S-K. The disclosure included in this section is prescribed by the SEC rules and does not necessarily align with how we or the compensation committee views the link between our performance and pay of our named executive officers. For further information regarding our compensation philosophy and how we seek to align executive compensation with our performance, refer to “Executive Compensation.” The use of the terms “compensation actually paid” (“CAP”) is required by the SEC’s rules. Neither CAP nor the total amount reported in the Summary Compensation Table reflect the amount of compensation actually paid, earned or received during the applicable year. Per SEC rules, CAP was calculated by adjusting the Summary Compensation Table total values for the applicable year as described in the footnotes to the following table.

Tabular Disclosure of Pay Versus Performance

The following table sets forth information concerning the comparison of our performance for the years ended December 31, 2024, 2023 and 2022 to the CAP paid to (1) our former President and Chief Executive Officer and Principal Executive Officer, Lloyd Segal , whom we refer to in this section as “PEO,” and (2) our other named executive officers, which include (a) for 2024, Maria Koehler, M.D., Ph.D. and Michael Zinda, Ph.D., (b) for 2023, Steve Forte and Dr. Koehler, and (c)